Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...

CDK 4/6 inhibitors (CDK4/6i) remain part of the standard first-line treatment for patients with hormone receptor–positive metastatic breast cancer, offering demonstrable improvements in both ...

Hormone modulating therapy (HMT) used for the treatment of breast cancer was associated with a 7% lower risk of developing Alzheimer's disease and related dementias later in life, according to a new ...

Hormone therapy in older women with breast cancer was associated with a reduced risk of subsequent dementia, a retrospective study of Medicare patients suggested. Breast cancer patients who received ...

Selective estrogen receptor modulators (SERMs) bind to hormone receptors, preventing estrogen from binding. Examples of SERMs approved by the FDA are tamoxifen (Nolvadex), raloxifene (Evista), and ...

If you have metastatic breast cancer that’s hormone receptor-positive (HR+) and HER2-negative, your treatment plan looks very different from how it might have decades ago. Instead of relying on ...

Please provide your email address to receive an email when new articles are posted on . The meta-analysis included more than 50 clinical trials and observational studies. Subjects included women who ...

Transcription Factors (TFs) are pivotal regulators of gene expression and have been implicated in a variety of diseases, including cancer, neurological disorders, autoimmune conditions, and metabolic ...